List of Lastacaft drug patents

Lastacaft is owned by Allergan.

Lastacaft contains Alcaftadine.

Lastacaft has a total of 2 drug patents out of which 0 drug patents have expired.

Lastacaft was authorised for market use on 28 July, 2010.

Lastacaft is available in solution/drops;ophthalmic dosage forms.

Lastacaft can be used as use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander.

The generics of Lastacaft are possible to be released after 23 December, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617695 ALLERGAN Ophthalmic compositions containing alcaftadine
Mar, 2027

(4 years from now)

US8664215 ALLERGAN Ocular allergy treatments with alcaftadine
Dec, 2027

(4 years from now)

Drugs and Companies using ALCAFTADINE ingredient

Market Authorisation Date: 28 July, 2010

Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LASTACAFT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in